^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    RareCyte

    i
    Other names: RareCyte | RareCyte, Inc. | RareCyte Inc | RareCyte Inc. | RareCyte, Inc.
    Related tests:
    Evidence

    News

    2ms
    Spatial remodeling of the tumor-immune microenvironment (TIME) on neoadjuvant chemo-immunotherapy (NCIT) in patients (pts) with hormone receptor positive (HR+) early breast cancer (eBC) by multiplex immunofluorescence (mIF). (ASCO 2026)
    P1 | " This is an exploratory analysis from trial NCT02999477 randomizing pts to a monotherapy run-in (A: nab-paclitaxel; B: pembrolizumab) followed by both in combination (NCIT)...At BL, RCB-0/I pts had numerically higher density of helper T cells (Th) (CD4+; median 2154.1 vs 890.0; p = .06), cytotoxic T cells (Tc) (CD8+; 728.1 vs 367.9; p = .08), activated Tc (6.1 vs 1.3; p = .06), APCs (HLA-ABC+, HLA-DR+: 124.6 vs 51.3; p = .36), and macrophages (CD68+CD206+; 63.4 vs 26.7; p = .25) vs RCB-II/III... TIME remodeling was heterogeneous, trending toward greater Tc and APC density and proximity to the tumor area in RCB 0/I."
    Clinical
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3) • MRC1 (Mannose Receptor C-Type 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel
    2ms
    Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes. (ASCO 2026)
    "The full, final text of this abstract will be available on May 21 at 05:00 PM EST."
    Clinical
    |
    AR (Androgen receptor) • SYP (Synaptophysin)
    almost2years
    RareCyte secures $20M financing to expand the Orion™ Spatial Biology platform including multiplex assay reagents, software and Precision Biology services (PRNewswire)
    "RareCyte, Inc...announced today the completion of a $20M financing from new and existing investors. The funding is expected to enable the Company to drive an expansion of the successful Orion Spatial Biology platform including commercializing new multiplex assays, reagent products, and software applications. The funding is also expected to support expansion of RareCyte's Precision Biology Services including spatial biology and liquid biopsy assays utilizing its Seattle, WA-based labs and scientific personnel performed under CLIA and ISO 13485 certifications. Global commercial expansion in regions outside the US will be amplified by the new funding."
    Financing
    2years
    Navigate BioPharma Services, Inc. announces collaboration with RareCyte, Inc. to provide enhanced spatial biology capabilities using the Orion™ Platform. (RareCyte Press Release)
    "Navigate BioPharma Services, Inc...announces the launch of its new multiplex spatial biology assay services for rapid, whole-slide imaging and analysis of tissue sections at subcellular resolution. These assays utilize the Orion™ platform from RareCyte, Inc. and feature ready-to-run assay panels, as well as customization to serve studies across multiple drug targets and therapeutic areas."
    Licensing / partnership
    over2years
    SOPHiA GENETICS enhances RareCyte precision biology services portfolio (PRNewswire)
    "SOPHiA GENETICS...announced that RareCyte Inc...is live on SOPHiA GENETICS. RareCyte has implemented the SOPHiA DDM™ Platform to complement its Precision Biology Services portfolio...The SOPHiA GENETICS technology will help RareCyte's team of scientists and engineers as they continue to develop next-generation products and services that advance precision medicine and biomedical research."
    Licensing / partnership